pharma · Lower limb spasticity · Pediatric lower limb (LL) spasticity (SP) caused by cerebral palsy (CP)
Merz Therapeutics
Merz Pharmaceuticals GmbH
Merz Pharmaceuticals is a pharma organization headquartered in Frankfurt am Main, DE. Primary therapeutic focus areas include Lower limb spasticity, Pediatric lower limb (LL) spasticity (SP) caused by cerebral palsy (CP)
frankfurt am main, DE HQ
2020 Founded
1,312 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- frankfurt am main, DE
- Founded
- 2020
- Employees
- 1,312
- Programs
- 2
- Drugs
- 4
- Patents
- 0
M602011072
Phase 3 · small molecule · Pediatric lower limb (LL) spasticity (SP) caused by cerebral palsy (CP)
M602011072 for Pediatric lower limb (LL) spasticity (SP) caused by cerebral palsy (CP) is a Phase 3 program (small_molecule) at Merz Pharmaceuticals GmbH with 1 ClinicalTrials.gov record(s).
Internal code M602011072
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Merz Pharmaceuticals GmbH
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Pediatric lower limb (LL) spasticity (SP) caused by cerebral palsy (CP)
- Status
- active
- Trials
- 1